Stephen Tirrell
Overview
Explore the profile of Stephen Tirrell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhuang J, Shirazi F, Singh R, Kuiatse I, Wang H, Lee H, et al.
Blood
. 2019 Feb;
133(14):1572-1584.
PMID: 30737236
Three proteasome inhibitors have garnered regulatory approvals in various multiple myeloma settings; but drug resistance is an emerging challenge, prompting interest in blocking upstream components of the ubiquitin-proteasome pathway. One...
2.
Hyer M, Milhollen M, Ciavarri J, Fleming P, Traore T, Sappal D, et al.
Nat Med
. 2018 Jan;
24(2):186-193.
PMID: 29334375
The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis. The therapeutic potential of this pathway has been validated by the clinical successes...
3.
Koenig E, Fisher C, Bernard H, Wolenski F, Gerrein J, Carsillo M, et al.
BMC Genomics
. 2016 Aug;
17:649.
PMID: 27535741
Background: MicroRNAs (miRNA) are varied in length, under 25 nucleotides, single-stranded noncoding RNA that regulate post-transcriptional gene expression via translational repression or mRNA degradation. Elevated levels of miRNAs can be...
4.
He H, Yang Y, Xiang Z, Yu L, Chouitar J, Yu J, et al.
J Biomark
. 2016 Jun;
2016:1274603.
PMID: 27247826
Objective. Use of tyramide signal amplification (TSA) to detect autophagy biomarkers in formalin fixed and paraffin embedded (FFPE) xenograft tissue. Materials and Methods. Autophagy marker regulation was studied in xenograft...
5.
Chattopadhyay N, Berger A, Koenig E, Bannerman B, Garnsey J, Bernard H, et al.
PLoS One
. 2015 Dec;
10(12):e0144825.
PMID: 26709701
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent,...
6.
Shah J, Jakubowiak A, OConnor O, Orlowski R, Harvey R, Smith M, et al.
Clin Cancer Res
. 2015 Nov;
22(1):34-43.
PMID: 26561559
Purpose: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma. Experimental...
7.
Smith D, Kalebic T, Infante J, Siu L, Sullivan D, Vlahovic G, et al.
Invest New Drugs
. 2015 Mar;
33(3):652-63.
PMID: 25777468
Purpose: Ixazomib is an investigational proteasome inhibitor with demonstrated antitumor activity in xenograft models of multiple myeloma (MM), lymphoma, and solid tumors. This open-label, phase 1 study investigated intravenous (IV)...
8.
Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen R, Dees E, et al.
Cancer Res
. 2010 Dec;
71(3):675-85.
PMID: 21148750
The mitotic kinase Aurora A is an important therapeutic target for cancer therapy. This study evaluated new mechanism-based pharmacodynamic biomarkers in cancer patients in two phase I studies of MLN8054,...
9.
Anderson K, Hess K, Kapoor M, Tirrell S, Courtemanche J, Wang B, et al.
Clin Cancer Res
. 2006 Mar;
12(6):1721-7.
PMID: 16551855
Purpose: The goals of this analysis were to (a) determine concordance of gene expression results from replicate experiments, (b) examine prediction agreement of multigene predictors on replicate data, and (c)...
10.
Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold D, et al.
J Mol Diagn
. 2005 Jul;
7(3):357-67.
PMID: 16049308
We examined how well differentially expressed genes and multigene outcome classifiers retain their class-discriminating values when tested on data generated by different transcriptional profiling platforms. RNA from 33 stage I-III...